CSI Market
Sign In | Register

Abcellera Biologics Inc (ABCL) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ABCL quarterly Cash Flow →
The cash flow figures below highlight longer-term patterns in how Abcellera Biologics Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-146.41
Depreciation & amortization18.44
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-2.20
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation55.79
Proceeds from Equity Method Investment, Dividends or Distributions30.11
Financial Instruments and Foreign Currency Transaction0.00
Operating Lease Right Of Use Asset Amortization Expense6.65
Increase Decrease In Accrued Royalties Receivable-
Increase Decrease In Operating Lease Liabilities-
Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable-
Change In Fair Value Of Contingent Consideration And Investments-
Gain On Contingent Consideration-
Gain Loss On Contingent Consideration And Investments4.53
Increase Decrease In Deferred Grant Income-3.64
Income taxes-29.84
Losses/ -gains on Investments net0.00
Increase (Decrease) in Receivables-55.62
Increase (Decrease) in Accounts Payable and Accrued Liabilities3.46
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital17.15
Other Noncash Income (Expense)-3.33
Other net0.00
Payments for (Proceeds from) Other Operating Activities-26.38
Discontinued operations0.00
Net Cash flow from Operating Activities-131.30
Investing Activities
Capital Expenditures-42.77
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities506.07
Payments to Acquire Marketable Securities-436.04
Real Estate Investments0.00
Proceeds From Receipt Of Grant Funding21.34
Investment In And Loans To Equity Accounted Investees-
Payments To Acquire Long Term Investments And Other Assets-
Payments To Acquire Proceeds From Long Term Investments And Other Assets-17.09
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Payments to Acquire Equity Method Investments-7.14
Sale of businesses0.00
Accounts payable0.00
Payments for (Proceeds from) Loans Receivable, Total33.27
Payments for (Proceeds from) Other Investing Activities0.00
Other Net30.11
Discontinued operations0.00
Net Cash Flow from Investing Activities87.75
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payment Of Liability For In Licensing Agreement-
Repayment Of Long Term Debt And Contingent Consideration-
Proceeds From Debt And Exercise Of Stock Options-
Proceeds From Convertible Debentures-
Payment Of Liability For In Licensing Agreement And Other-
Repayment Of Liability For In Licensing Agreement And Contingent Consideration-
Proceeds From Liabilities And Exercise Of Stock Options29.73
Payments Of Liability For In Licensing Agreement And Other-15.65
Payments Of Contingent Consideration And Other-
Proceeds From Long Term Liabilities And Stock Options Exercised-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities14.08
Effect of exchange rate on cash flow1.10
Discontinued operations0.00
Free Cash Flow-174.07
Total Cash Flow-28.37
4 historic quarters locked

Sign in to unlock the full Abcellera Biologics Inc cash flow history.

Sign In Create Free Account

About Abcellera Biologics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 24, 2026
  • Source: abcl-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001703057-26-000012

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document